Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Changing burden of Hepatitis C virus infection in the United States

The latest issue of the Annals of Internal Medicine makes predictions on the changing burden of Hepatitis C virus infection.

News image

Chronic hepatitis C virus (HCV) infection causes a substantial health and economic burden in the United States. With the availability of direct-acting antiviral agents, recently approved therapies and those under development, and 1-time birth-cohort screening, the burden of this disease is expected to decrease.

Dr Chhatwal and colleagues from Texas, USA predicted the effect of new therapies and screening on chronic HCV infection and associated disease outcomes.

The research team evaluated existing and anticipated therapies and screening for HCV infection in the United States.

The team assessed the total HCV-infected population in the United States.

Outcomes included the number of cases of chronic HCV infection and outcomes of advanced-stage HCV infection.
Chronic HCV cases decreased from 3.2 million in 2001 to 2.3 million in 2013
Annals of Internal Medicine

The number of cases of chronic HCV infection decreased from 3.2 million in 2001 to 2.3 million in 2013.

The researchers report that 1-time birth-cohort screening beginning in 2013 is expected to identify 487,000 cases of HCV infection in the next 10 years.

In contrast, 1-time universal screening could identify 933,700 cases.

With the availability of highly effective therapies, HCV infection could become a rare disease in the next 22 years.

The team found that recently approved therapies for HCV infection and 1-time birth-cohort screening could prevent approximately 124,200 cases of decompensated cirrhosis, 78,800 cases of hepatocellular carcinoma, 126,500 liver-related deaths, and 9900 liver transplantations by 2050.

Increasing the treatment capacity would further reduce the burden of HCV disease.

Dr Chhatwal's team concludes, "New therapies for HCV infection and widespread implementation of screening and treatment will play an important role in reducing the burden of HCV disease."

"More aggressive screening recommendations are needed to identify a large pool of infected patients."

Ann Intern Med 2014; 161(3): 170-180
06 August 2014

Go to top of page Email this page Email this page to a colleague

 04 March 2015

Advanced search
 04 March 2015 
Progression of Barrett's
 04 March 2015 
Multidisciplinary management of rectal cancer
 04 March 2015 
Management of IBD
 03 March 2015 
Risk of anastomotic leak after colectomy
 03 March 2015 
GI bleeding in chronic kidney disease patients on aspirin
 03 March 2015 
EPHX1 polymorphism and esophageal cancer risk
 02 March 2015 
Liver disease in patients awaiting liver transplant
 02 March 2015 
Genes and early diagnosis of IBD
 02 March 2015 
Assessment of GERD
 27 February 2015 
Obesity and weight-loss therapy
 27 February 2015 
MRE performance in staging liver fibrosis
 27 February 2015 
Bleeding in diverticulosis
 26 February 2015 
Familial colorectal cancer risk and primary cancer
 26 February 2015 
Herbal products and the liver
 26 February 2015 
Questionnaires for GERD
 25 February 2015 
Exercise and NAFLD
 25 February 2015 
IBD in Korea
 25 February 2015 
Immunosuppressive therapy and T. whipplei
 24 February 2015 
Clinical trials in pediatric IBD
 24 February 2015 
Reducing health care costs in IBD
 24 February 2015 
GI bleeding after anticoagulation interruption
 23 February 2015 
Visceral abdominal obesity and IBS
 23 February 2015 
Crohn's outcomes with infliximab
 23 February 2015 
Intestinal microbiota and celiac disease
 20 February 2015 
H. pylori eradication
 20 February 2015 
Antiviral treatment and Hep C outcomes
 20 February 2015 
C. diff testing in IBD
 19 February 2015 
Intestinal microbiota in IBS
 19 February 2015 
Peptic ulcer bleeding mortality in liver disease
 19 February 2015 
Fecal microbial transplant in active Crohn's disease
 18 February 2015 
Genetic testing and GI cancers
 18 February 2015 
Placebo analgesia in functional abdominal pain
 18 February 2015 
Successful Hep C virus therapy
 17 February 2015 
Quality measures and colonoscopist selection
 17 February 2015 
Global incidence of esophageal cancer
 17 February 2015 
Anti-viral treatment and survival in Hep C
 16 February 2015 
Saliva for the diagnosis of GERD
 16 February 2015 
H pylori eradication therapy
 16 February 2015 
Medical marijuana for digestive disorders
 13 February 2015 
Prevalence of microscopic colitis
 13 February 2015 
Beta-blockers in cirrhosis
 13 February 2015 
Liver disease and peptic ulcer bleeding
 12 February 2015 
Liver disease in chronic Hep C
 12 February 2015 
Patient-reported outcomes in Hep C
 12 February 2015 
Patientsí colonoscopist selection
 11 February 2015 
Hepatic decompensation in Hep C cirrhosis
 11 February 2015 
Guidelines for the diagnosis of hepatocellular carcinoma
 11 February 2015 
NAFLD and CVD
 10 February 2015 
Percutaneous endoscopic gastrostomy
 10 February 2015 
Factors that influence hepatic steatosis
 10 February 2015 
Gene variants and Crohn's susceptibility
 09 February 2015 
Factors that influence gallstone surgery
 09 February 2015 
Factors associated with increased mortality in cirrhosis
 09 February 2015 
Use of immunomodulators in IBD
 06 February 2015 
Colorectal cancer risk in IBD
 06 February 2015 
H. pylori and peptic ulcer bleeding
 06 February 2015 
IBS and somatization
 05 February 2015 
GERD, dyspepsia and IBS symptoms
 05 February 2015 
Thalidomide and refractory Crohn's
 05 February 2015 
Quality of life in Crohn's after antitumor necrosis factor agents

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us